GLP drugs offer a comprehensive approach to improving metabolic health
L-carnitine supplementation in non-alcoholic fatty liver disease: Effects on intrahepatic triglyceride, muscle lipid fractions and liver mitochondrial energetics-results from a pilot randomised trial
Neither has been evaluated by the FDA for the diagnosis, treatment, cure, or prevention of any disease
In this context, we give a brief overview of the principal transporter proteins identified in different organs, including kidneys, liver, and intestines (Table 1)
To elucidate the influence of GLP-1R upregulation in LS GLP-1R neurons on food intake, we used a specific AAV vector encoding Cre-inducible mouse GLP-1Rs, complemented with a hemagglutinin (HA) epitope tag, for targeted injection into the dLS of GLP-1R-ires-Cre mice (Supplemental Figure 5A)
34, 2015, pp